Date : 04 February 2026

Description: They usually explore various advanced implantable neuromodulation devices, as well as topical and oral pharmaceutical products.
Description: It unveiled variations in Sacroiliac (SI) Joint Fusion, Kyphoplasty, and Radiofrequency (RF) Ablation, etc.
Description: This mainly provides specialized interventional therapies to treat chronic joint pain.
Description: It facilitates solutions through its DePuy Synthes MedTech division and novel medicine portfolio.
Description: This specialises in non-surgical to robotic-assisted surgical solutions, including restorative therapies, biologics, and surgical reconstruction.
Description: A firm focuses on radiofrequency ablation, vertebral augmentation, and joint reconstruction technologies.
Description: It plays a major role in developing viscosupplementation for knee osteoarthritis (OA).
Description: This company offers solutions for chronic joint pain through its proprietary hyaluronic acid (HA) technology.
Description: It facilitates non-surgical hyaluronic acid (HA) injections for osteoarthritis (OA) & peripheral nerve stimulation (PNS) for nerve-related chronic pain.
Description: This introduced several non-opioid, targeted therapies to manage chronic joint pain, like ZILRETTA, iovera, etc.
The global chronic pain therapy solutions for joints market size was estimated at USD 5.15 billion in 2025 and is predicted to increase from USD 5.4 billion in 2026 to approximately USD 8.28 billion by 2035, expanding at a CAGR of 4.86% from 2026 to 2035.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
Speak with a healthcare analyst about your research, consulting, or platform needs.